[en] Second-generation antipsychotics (SGA), especially clozapine and olanzapine, are associated with an increased metabolic risk. Recent research showed that plasma adiponectin levels, an adipocyte-derived hormone that increases insulin sensitivity, vary in the same way in schizophrenic patients as in the general population according to gender, adiposity and metabolic syndrome (MetS). The aim of the present study was to investigate whether different SGAs differentially affect plasma adiponectin levels independent of body mass index (BMI) and MetS status. 113 patients with schizophrenia (65.5% males, 32.3years old) who were free of antipsychotic medication were enrolled in this open-label prospective single-center study and received either risperidone (n=54) or olanzapine (n=59). They were followed prospectively for 12weeks. Average daily dose was 4.4mg/day for risperidone and 17.4mg/day for olanzapine. Plasma adiponectin levels as well as fasting metabolic parameters were measured at baseline, 6weeks and 12weeks. The two groups had similar baseline demographic and metabolic characteristics. A significant increase in body weight was observed over time. This increase was significantly larger in the olanzapine group than in the risperidone group (+7.0kg versus +3.1kg, p<0.0002). Changes in fasting glucose and insulin levels and in HOMA-IR, an index of insulin resistance, were not significantly different in both treatment groups. MetS prevalence increased significantly more in the olanzapine group as compared to the risperidone groups where the prevalence did not change over time. We observed a significant (p=0.0015) treatment by time interaction showing an adiponectin increase in the risperidone-treated patients (from 10,154 to 11,124ng/ml) whereas adiponectin levels decreased in olanzapine treated patients (from 11,280 to 8988ng/ml). This effect was independent of BMI and the presence/absence of MetS. The differential effect of antipsychotic treatment (risperidone versus olanzapine) on plasma adiponectin levels over time, independent of changes in waist circumference and antipsychotic dosing, suggests a specific effect on adipose tissues, similar to what has been observed in animal models. The observed olanzapine-associated reduction in plasma adiponectin levels may at least partially contribute to the increased metabolic risk of olanzapine compared to risperidone.
Collette, Julien ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Peuskens, J.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
American Diabetes Association Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004, 27:596-601.
Ader M., Kim S.P., Catalano K.J., Ionut V., Hucking K., Richey J.M., Kabir M., Bregman N. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005, 54:862-871.
Ader M., Garvey W.T., Phillips L.S., Nemeroff C.B., Gharabawi G., Mahmoud R., Greenspan A., Berry S.A., Musselman D.L., Morein J., Zhu Y., Mao L., Bergman R.N. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J. Psychiatr. Res. 2008, 42:1076-1085.
Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 2001, 62(Suppl 7):S22-S31.
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004, 27:596-601.
Bai Y.M., Chen J.Y., Yang W.S., Chi Y.C., Lin C.C.Y.J., Liou Y.J., Wang Y.C., Su T.P., Chou P., Chen J.-Y. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia. Schizophr. Res. 2009, 111:1-8.
Baptista T., Mata L., Teneud M., De Quijada H., Han W., Hernandez L. Effects of long term administration of clozapine on body weight and food intake in rats. Pharmacol. Biochem. Behav. 1993, 45:51-54.
Baptista T., Contreras Q., Teneud L., Albornoz M., Acosta A., Paez X. Mechanisms of neuroleptic-induced obesity in female rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22:187-189.
Baptista T., de baptista E.A., Lalonde J., Plamondon J., Kin N.M., Beaulieu S. Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:1305-1311.
Birkenaes A., Birkeland K., Friis S., Opjordsmoen S., Andreassen O. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions. J. Clin. Psychopharmacol. 2009, 29(2):109-116.
B-Bridge International, Inc. Human Adiponectin ELISA kit User Manual 2002.
Chiu C.C., Chen C.-H., Chen B.-Y., Yu S.-H., Lu M.-L. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:866-870.
Coccurello R., Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol. Ther. 2010, 127(3):210-251.
Cook J.R., Semple R.K. Hypoadiponectinemia-cause or consequence of human"insulin resistance"?. J. Clin. Endocrinol. Metab. 2010, 95(4):1544-1554.
Cooper G., Pickavance L., Wilding J., Halford J., Goudie A. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology 2005, 181:80-89.
Cooper G., Pickavance L., Wilding J., Halford J., Goudie A. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J. Psychopharmacol. 2007, 21:405-413.
Cope M., Nagy T., Fernandez J., Geary N., Casey D., Allison D. Antipsychotic-induced weight gain: development of an animal model. Int. J. Obes. 2005, 29:607-614.
De Hert M., Hanssens L., van Winkel R., Wampers M., Van Eyck D., Scheen A., Peuskens J. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia. A case series of switching to aripiprazole. Diabetes Care 2006, 29:10.
De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 2006, 83(1):87-93.
De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin. Pract. Epidemiol. Ment. Health 2006, 2(14).
De Hert M., Hanssens L., van Winkel R., Wampers M., Van Eyck D., Scheen A., Peuskens J. A case series: evaluation of the metabolic safety of aripiprazole. Schizopr. Bull. 2007, 33(3):823-830.
De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., Möller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry 2009, 24(6):412-424.
De Hert M., Correll C.U., Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr. Res. 2010, 117(1):68-74.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Position statement on the diagnosis and classification of diabetes mellitus. Diabetes Care 2008, 31(Suppl 1):S55-S60.
Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
Fell M., Marshall K., Williams J., Neill J. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J. Psychopharmacol. 2004, 18:149-155.
Fell M., Neill J., Rao C., Marshall K. Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. Psychopharmacology 2005, 182:499-507.
Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167:686-693.
Goudie A., Smith J., Halford J. Characterization of olanzapine induced weight gain in rats. J. Psychopharmacol. 2002, 16:291-296.
Goudie A., Cooper G., Halford J. Antipsychotic induced weight gain. Diabetes Obes. Metab. 2005, 7:478-487.
Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239. For the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association.
Gueorguieva R., Krystal J.H. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch. Gen. Psychiatry 2004, 61:310-317.
Guerre-Millo M. Adiponectin: an update. Diabetes Metabol. 2008, 34:12-18.
Hanssens L., van Winkel R., Wampers M., Van Eyck D., Schenn A., Reginster J.-Y., Collette J., Peuskens J., De Hert M. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Shizophr. Res. 2008, 106:308-314.
Haupt D.W., Newcomer J.W. Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry 2001, 62(27):15-26.
Haupt D. Differential metabolic effects of antipsychotic treatments. Eur. Neuropsychopharmacol. 2006, 16(Suppl 3):149-152.
Houseknecht K.L., Robertson A.S., Zavadoski W., Gibbs E.M., Johnson D.E., Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007, 32:289-297.
Jin H., Meyer J.M., Jeste D.V. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr. Res. 2004, 71(2-3):195-212.
Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizopr. Res. 2008, 100(1-3):70-85.
Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005, 439-451.
Kato M.M., Currier M.B., Gomez C.M., Hall L., Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. J. Clin. Psychiatry 2004, 6:74-77.
Koller E., Schneider B., Bennett K., Dubitsky G. Clozapine associated diabetes. Am. J. Med. 2001, 111:716-723.
Koller E.A., Weber J., Doraiswamy P.M., Schneider B.S. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J. Clin. Psychiatry 2004, 65:857-863.
Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
Lihn A.S., Pedersen S.B., Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes. Rev. 2005, 6:13-21.
Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostatis model assessment: insulin resistance and beta-cell function from fasting plasma insulin concentrations in man. Diabetologia 1985, 28:412-419.
Mathieu P., Lemieux I., Després J.P. Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther. 2010, 87(4):407-416.
McQuade R.D., Stock E., Marcus R., Jody D., Gharbia N.A., Vanveggel S., Archibald D., Carson W.H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 2004, 65(Suppl 18):47-56.
Meyer J.M., Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004, 70(1):1-17.
Minet-Ringuet J., Even P.C., Valet P., CarpénÉ C., Visentin V., PrÉvot D., Daviaud D., Quignard-Boulange A., TomÉ D., de Beaurepaire R. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol. Psychiatry 2007, 12:562-571.
Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry 2007, 68(Suppl 1):20-27.
Newcomer J.W. Metabolic syndrome and mental illness. Am. J. Manag. Care 2007, 13(Suppl 7):170-177.
Oriot P., Feys J.L., Mertens de Wilmars S., Misson A., Ayache L., Fagnart O., Gruson D., Luts A., Jamart J., Hermans M.P., Buysschaert M. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naÏve schizophrenic patients treated with atypical antipsychotic drugs: a nine month prospective study. Diabetes Metabol. 2008, 34:490-496.
Ruige J.B., Ballaux D.P., Funahashi T., Mertens I.L., Matsuzawa Y., Van Gaal L.F. Resting metabolic rate is an important predictor of serum adiponectin concentrations: potential implications for obesity-related disorders. Am. J. Clin. Nutr. 2005, 82(1):21-25.
Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., Kissling W., Davis J.M., Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2010, 123(2-3):225-233.
Scheen A.J., De Hert M. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metabol. 2007, 33(3):169-175.
Secher A., Husum H., Holst B., Egerod K.L., Mellerup E. Risperidone treatment increases CB1 receptor binding in rat brain. Neuroendocrinology 2010, 91(2):155-168.
Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., Ismail K. First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 2008, 192(6):406-411.
Smith R.C., Lindenmayer J.-P., HU Q., Kelly E., Viviano T.V., Cornwell J., Vaidhyanathaswamy S., Marcovina S., Davis J.M. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Schizophr. Res. 2010, 120:204-209.
Tiihonen J., Lönnquist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population based cohort study (FIN11 study). Lancet 2009, 374(9690):620-627.
Togo T., Kojima K., Shoji M., Kase A., Uchikado H., Katsuse O., Iseki E., Kosaka K. Serumadiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int. Clin. Psychopharmacol. 2004, 19:37-40.
Trujillo M.E., Scherer P.E. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Inter. Med. 2005, 257:167-175.
van Winkel R., de Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J. Clin. Psychiatry 2006, 67(10):1493-1500.
van Winkel R., De Hert M., Wampers M., Van Eyck D., Hanssens L., Scheen A., Peuskens J. Major changes in glucose metabolism including new-onset diabetes within 3months after initiation or switch of atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2008, 69:472-479.
Vestri H., Maianu L., Moellering D., Garvey W. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis and antilypolysis. Neuropsychopharmacology 2007, 32:765-772.
Weinmann S., Read J., Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr. Res. 2009, 113:1-11.
Wolfinger R.D. Covariance structure selection in general mixed models. Commun. Stat. Simul. Comput. 1993, 22:1079-1106.
Wolfinger R.D. An example of using mixed models and PROC MIXED for longitudinal data. J. Biopharm. Stat. 1997, 7:381-500.
Wolfinger R.D., Chang M. Comparing the SAS GLM and MIXED Procedures for Repeated Measures 1998, SAS Institute Inc, Cary, NC. http://www.support.sas.com/rnd/app/papers/mixedglm.pdf.
Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7:941-946.
